BASF introduces new solutions for the personal care market
Wax-based and readily biodegradable: Euperlan OP White and Cegesoft Peel.
At SCS Formulate on 13 & 14 November in Coventry, BASF will share stand 500 with its European distribution organization BTC Europe and present the latest solutions to meet the demands of the personal care market.
Readily biodegradable, wax-based opacifier dispersion and exfoliating beads for personal care products
BASF Care Creations will showcase two new products that answer the needs of today’s environmentally conscious consumers. “We are constantly seeking innovative and more sustainable solutions for the personal care industry. Consumer trends and needs clearly show us the way. With our new ingredients Euperlan OP White and Cegesoft Peel we can help our customers to develop winning products supporting both the consumers’ well-being and eco-conscience,” said Dirk Mampe, Vice President Business Management Personal Care Solutions Europe.
Euperlan OP White is a wax-based, readily biodegradable and cold processable opacifier dispersion with a superior white appearance for surfactant formulations. The product meets today’s demand for ecological friendly ingredients and its unique properties make it particularly suitable for eco-label conforming skin and hair cleansing formulations. BASF is the leading supplier of cold processable wax dispersions for personal care that provide optical effects in rinse off products. Euperlan OP White complements BASF’s current portfolio of pearlizing wax dispersions and can be used as an alternative to synthetic polymeric opacifiers.
Cegesoft Peel consists of round wax beads that provide a gentle and mild exfoliation. Mainly derived from natural and renewable resources, Cegesoft Peel is a readily biodegradable and environmentally friendly alternative to sharp-edged abrasives and non-degradable beads (often referred to as microplastic beads).
Hyalurosmooth – counteracting harmful effects of daily stress
Daily stresses are known to translate into cutaneous stress, with cortisol as its main mediator. Hyalurosmooth represses the damaging impact of cortisol on the skin, restoring collagen type I and hyaluronic acid that are affected. Bringing the positive effects of a mindful lifestyle – rested from the inside – Hyalurosmooth helps the skin recover its hydration and radiance. Extracted from the Indian Cassia angustifolia, Hyalurosmooth is IECIC-listed.
As part of the Inspire presentation program, Axel Boettcher from BTC Europe will be presenting new data on Hyalurosmooth.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance